Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)

Inclusion Criteria: * Liver metastases of colon cancer or rectal predominant (histological evidence obtained on the primary tumor or liver metastases) * Isolated (no extra-hepatic metastasis, primary tumor resected) * No access to curative hepatectomy (R0 resection foreseeable or not leaving less than 30% residual non-tumor liver normally vascularized), or requiring complex hepatectomy, very large (5 or more segments) and / or risked (class II CPP) * which at least one measurable by RECIST (\>2 cm, or \>1 cm if Computed tomography (CT) spiraled) * Or extra-hepatic disease of small size potentially accessible to a resection (one or two lung metastases, lymphadenopathy localized accessible to curative resection) * colon or rectal primary tumor : resected or asymptomatic * Progression after first line chemotherapy to treat the metastatic disease, all types of treatment allowed except intra-arterial Bevacizumab * Age \>18 years \3 months * Bilirubin \150/100 mm Hg despite hypertensive treatment) * Heart Failure \>Grade II of the New York Heart Association (NYHA) (class II-III-IV)severe renal failure * History and / or presence of bleeding disorders and/or thrombotic \